3100 Phase Ib/II study of the pan-cyclin-dependent kinase (CDK) inhibitor roniciclib (BAY 1000394) in combination with chemotherapy as first-line therapy in subjects with extensive disease small cell lung cancer (ED-SCLC)
Saved in:
| Published in | European journal of cancer (1990) Vol. 51; p. S634 |
|---|---|
| Main Authors | , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Elsevier Ltd
01.09.2015
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Author | Kim, D.W. Pennell, N.A. Rajagopalan, P. Cho, B.C. Dy, G.K. Nogai, H. Ocker, M. Zalcman, G. Besse, B. Govindan, R. Barlesi, F. |
|---|---|
| Author_xml | – sequence: 1 givenname: B.C. surname: Cho fullname: Cho, B.C. – sequence: 2 givenname: G.K. surname: Dy fullname: Dy, G.K. – sequence: 3 givenname: R. surname: Govindan fullname: Govindan, R. – sequence: 4 givenname: D.W. surname: Kim fullname: Kim, D.W. – sequence: 5 givenname: N.A. surname: Pennell fullname: Pennell, N.A. – sequence: 6 givenname: G. surname: Zalcman fullname: Zalcman, G. – sequence: 7 givenname: B. surname: Besse fullname: Besse, B. – sequence: 8 givenname: H. surname: Nogai fullname: Nogai, H. – sequence: 9 givenname: P. surname: Rajagopalan fullname: Rajagopalan, P. – sequence: 10 givenname: M. surname: Ocker fullname: Ocker, M. – sequence: 11 givenname: F. surname: Barlesi fullname: Barlesi, F. |
| BookMark | eNqNkc9uEzEQxleoSKSFR0CaY3JYau__FQLUpgUiIoFUOHCyvPaYdbqxI9sp7MPyLngT4FAJlYstj77vN-P5TpMTYw0myXNKXlBCq_Mb0pZt2pCindNqkdO6oGn5KJnRpm5T0pTZSTL7K3mSnHq_IYTUTUFmyc-cEgKfeu4RVt35agU-7OUIVkHoEXbcpGIUgzapxB0aiSbArTaTfL68-rAAbXrd6WAdOGu00FHbwfzy4itEMMnbYpKAsNsuuoK2Br7r0IPocWtjB8d3I3APSjsf0tgH4U812vy-26AI_ujBHwGN13cIUnucRvBbPgwgMB7D3nwDwY1AB_Prq_RmuV4uniaPFR88Pvt9nyVf3l5_Xr5P1x_frZYX61RkVV6mssGKdpWsVa1aXtVFS5Bnsmq7QtJOoKrbqZapXBR1J5QoVV2ovGy7JqeqlPlZUh65wlnvHSq2c3rL3cgoYVNG7JARmwJg8XXIiJXR9_KeT-hw2FJwXA8Put8c3Ri_dqfRMS80xg1I7eLWmLT6QcLre4Qpai34cIsj-o3dOxP3xijzGSNHyMSg1YEwAV79G_AfA_wC8mXW7g |
| CitedBy_id | crossref_primary_10_1021_acschembio_6b00074 |
| ContentType | Journal Article |
| Copyright | 2015 European Cancer Congress European Cancer Congress |
| Copyright_xml | – notice: 2015 European Cancer Congress – notice: European Cancer Congress |
| DBID | AAYXX CITATION |
| DOI | 10.1016/S0959-8049(16)31741-5 |
| DatabaseName | CrossRef |
| DatabaseTitle | CrossRef |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1879-0852 |
| EndPage | S634 |
| ExternalDocumentID | 10_1016_S0959_8049_16_31741_5 S0959804916317415 1_s2_0_S0959804916317415 |
| GroupedDBID | --- --K --M .1- .55 .FO .GJ .~1 0R~ 1B1 1P~ 1RT 1~. 1~5 29G 3O- 4.4 457 4G. 53G 5GY 5RE 5VS 6PF 7-5 71M 8P~ 9JM AABNK AAEDT AAEDW AAIKJ AAKOC AALRI AAOAW AAQFI AAQXK AATTM AAWTL AAXKI AAXUO AAYWO ABBQC ABFNM ABGSF ABJNI ABLJU ABMAC ABMZM ABOCM ABUDA ABWVN ABXDB ACDAQ ACIEU ACIUM ACPRK ACRLP ACRPL ACVFH ADBBV ADCNI ADEZE ADMUD ADNMO ADUVX AEBSH AEHWI AEIPS AEKER AENEX AEUPX AEVXI AFFNX AFJKZ AFPUW AFRAH AFRHN AFTJW AFXIZ AGCQF AGHFR AGQPQ AGRDE AGUBO AGYEJ AHHHB AIEXJ AIGII AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX APXCP ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV CS3 DU5 EBS EFJIC EFKBS EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-2 G-Q GBLVA HED HMK HMO HVGLF HZ~ IHE J1W K-O KOM M29 M41 MO0 N9A O-L O9- OAUVE OC~ OO- OZT P-8 P-9 P2P PC. Q38 R2- ROL RPZ SAE SCC SDF SDG SDP SEL SES SEW SPCBC SSH SSU SSZ T5K UV1 WUQ X7M XPP Z5R ZGI ZXP ~G- AACTN AFCTW AFKWA AJOXV AMFUW RIG AAIAV ABLVK ABYKQ AHPSJ AJBFU DOVZS EFLBG LCYCR ZA5 AAYXX AGRNS CITATION |
| ID | FETCH-LOGICAL-c2635-d8e61b6d7f7f9a67490ea2d69b4d1bcef7974902f3c47bcfc5f74f359b831f5d3 |
| IEDL.DBID | .~1 |
| ISSN | 0959-8049 |
| IngestDate | Thu Apr 24 22:54:33 EDT 2025 Tue Jul 01 01:05:18 EDT 2025 Fri Feb 23 02:18:44 EST 2024 Sun Feb 23 10:18:55 EST 2025 Tue Aug 26 16:31:39 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Language | English |
| License | https://www.elsevier.com/tdm/userlicense/1.0 |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c2635-d8e61b6d7f7f9a67490ea2d69b4d1bcef7974902f3c47bcfc5f74f359b831f5d3 |
| ParticipantIDs | crossref_primary_10_1016_S0959_8049_16_31741_5 crossref_citationtrail_10_1016_S0959_8049_16_31741_5 elsevier_sciencedirect_doi_10_1016_S0959_8049_16_31741_5 elsevier_clinicalkeyesjournals_1_s2_0_S0959804916317415 elsevier_clinicalkey_doi_10_1016_S0959_8049_16_31741_5 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | September 2015 |
| PublicationDateYYYYMMDD | 2015-09-01 |
| PublicationDate_xml | – month: 09 year: 2015 text: September 2015 |
| PublicationDecade | 2010 |
| PublicationTitle | European journal of cancer (1990) |
| PublicationYear | 2015 |
| Publisher | Elsevier Ltd |
| Publisher_xml | – name: Elsevier Ltd |
| SSID | ssj0007840 |
| Score | 2.1484358 |
| SourceID | crossref elsevier |
| SourceType | Enrichment Source Index Database Publisher |
| StartPage | S634 |
| SubjectTerms | Hematology, Oncology and Palliative Medicine |
| Title | 3100 Phase Ib/II study of the pan-cyclin-dependent kinase (CDK) inhibitor roniciclib (BAY 1000394) in combination with chemotherapy as first-line therapy in subjects with extensive disease small cell lung cancer (ED-SCLC) |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S0959804916317415 https://www.clinicalkey.es/playcontent/1-s2.0-S0959804916317415 https://dx.doi.org/10.1016/S0959-8049(16)31741-5 |
| Volume | 51 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La9wwEBYhhdJL6ZNuH2EOPewelF2vZcs-bp2E3aYJhTSQnoQlS8R044T15pBL_2n_S2dkOdvSwEIPBltoJKORZj6NZkaMfXQ6s7koyVUKtyioAkqe4SunxEP4mKj0uTtPTtP5ufh8kVzssKKPhSG3yiD7O5nupXUoGYfRHN_U9fiMLFgZAlxEFJHsAs2FkDTL939u3Dxk5oMiO3MX1t5E8XQt-MJhlI58Izx5WD_9oXOOnrGnASzCrPuf52zHNi_Y45NwHP6S_SK7OXy9RE0ECz1eLMBni4VrB4jrABc6N3cU-8j7u27X8KNuqPqwODgeQd1c1hrX9Ap8ilzspdYw_DT7DpGPpxVUBXBscP_sWQhktwVk9FWI3LqDsgVXI4bkBFihL0Wy9laTkaftaLy1nXzlIZwJQXtVLpdAJwewRJEDhibgCoaHB_ys-FKMXrHzo8NvxZyH-xq4oZQ2vMpsGum0kk66vEylyCe2nFZprkUVaWOdzKls6mIjpDbOJE4KFye5zuLIJVX8mu021419w0CUtkosbtw1wh09SXU8RWiYxVqaSSUqM2Ci55IyIZk53amxVBuvNWSuIuYq_PLMVcmA7d-T3XTZPLYRpP0UUH2oKgpXhfpmG6F8iNC2QUS0KlLtVE3UP9N4wLJ7yr9WwvZO3_4_6Tv2BKFg0nnPvWe769Wt_YBwa633_HraY49mi-P56W-5hyEq |
| linkProvider | Elsevier |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La9wwEBZhA20vpU-6fc6hh92Duuu1bNnHrZOw7j4oJIH0JCxZIqYbJ6w3h_zY_peOZHnT0sBCDwZb-LONR5r5NJoZEfLZyESnrLChUjhFQRNQ0ARPqS08hIcKCle7c7mKZ-fs20V0cUCyLhfGhlV63d_qdKetfcvI_83RTVWNTq0HK0GCi4wi4C7R_NBWp4p65HCaz2ernULmicuLbD1eCLhP5Gkf4hoHQTx0z6HRwybqD7Nz8ow89XwRpu0nPScHun5BHi39ivhL8su6zuH7JRojyOUoz8EVjIVrA0jtAMc6VXc2_ZF2291u4WdV29sH2dF8CFV9WUkc1htwVXLxLZWEwdfpDwhcSi2ztwD-HpxCOymCdd0CyvrKJ2_dQdGAqZBGUstZoWtFWHMrrZ-naTHO4W7D5cEvC0FzVazXYBcPYI1aB5TtgxsYHB_R02yRDV-R85Pjs2xG_ZYNVNmqNrRMdBzIuOSGm7SIOUvHupiUcSpZGUilDU9t28SEinGpjIoMZyaMUpmEgYnK8DXp1de1fkOAFbqMNM7dJTIeOY5lOEF2mISSq3HJStUnrJOSUL6eud1WYy3uA9dQuMIKV-CVE66I-uTLDnbTFvTYB4i7LiC6bFXUrwJNzj4gfwioG68lGhGIZiLG4p-e3CfJDvnXYNj_0rf_D_1EHs_OlguxyFfzd-QJMsOoDaZ7T3rbza3-gOxrKz_60fUbnncj2w |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=3100+Phase+Ib%2FII+study+of+the+pan-cyclin-dependent+kinase+%28CDK%29+inhibitor+roniciclib+%28BAY+1000394%29+in+combination+with+chemotherapy+as+first-line+therapy+in+subjects+with+extensive+disease+small+cell+lung+cancer+%28ED-SCLC%29&rft.jtitle=European+journal+of+cancer+%281990%29&rft.au=Cho%2C+B.C.&rft.au=Dy%2C+G.K.&rft.au=Govindan%2C+R.&rft.au=Kim%2C+D.W.&rft.date=2015-09-01&rft.pub=Elsevier+Ltd&rft.issn=0959-8049&rft.eissn=1879-0852&rft.volume=51&rft.spage=S634&rft.epage=S634&rft_id=info:doi/10.1016%2FS0959-8049%2816%2931741-5&rft.externalDocID=S0959804916317415 |
| thumbnail_m | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F09598049%2FS0959804915X00165%2Fcov150h.gif |